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Determination of Impurities in 
Pharmaceuticals: Why and How?
Kung-Tien Liu and Chien-Hsin Chen
Abstract
The presence of impurities, particularly the API-related impurities, i.e., 
degradation-related impurities (DRIs) and interaction-related impurities (IRIs), 
may affect the quality, safety, and efficacy of drug products. Since the regula-
tory requirements and management strategies are required to be established and 
complied, sources of impurities shall be carefully classified prior to take subse-
quent steps such as development of analytical methods and acceptance criteria. 
Current international regulatory requirements for the management of impurities 
in pharmaceuticals were reviewed. Procedures for the identification of DPIs in 
pharmaceuticals, i.e., ethyl cysteinate dimer, (R)-N-methyl-3-(2-bromophenoxy) 
-3-phenylpropanamine, sestamibi, etc., using high-performance liquid chroma-
tography tandem mass spectrometry (LC-MS/MS) were studied. Scheme for the 
establishment of analytical methods and acceptance criteria of process-related 
impurities (PRIs) and DRIs in accordance with the requirements of International 
Council for Harmonization (ICH) and algorithm to perform the identification 
of DPIs by using LC-MS/MS has been proposed. Practice of kinetic study to 
distinguish PRIs and DRIs, determination of the potential core fragments coupled 
with a predicted list of relevant transformations for conducting MS/MS scans, 
applications of stable isotope distribution patterns or natural abundances, practice 
of mass balance, etc., have been well demonstrated to justify the reliabilities of 
identification results.
Keywords: pharmaceutical products, impurities, regulatory requirements, analytical 
strategy, structural identification, validation, verification, LC-MS/MS, kinetic study, 
stable isotope distribution patterns
1. Introduction
As defined by the United States Pharmacopeial (USP), impurity is “any compo-
nent of a drug substance that is not the chemical entity defined as the drug sub-
stance and in addition, for a drug product, any component that is not a formulation 
ingredient” [1].
Impurities in drug substance (i.e., active pharmaceutical ingredient, API) or 
drug product can arise due to synthetic/manufacturing processes, degradation, 
storage conditions, container, excipients, or contamination. They can be identified 
or unidentified, volatile or nonvolatile, organic or inorganic species [1–3].
Since different regulatory requirements and management strategies are required 
to be established and complied, sources of impurities shall be carefully classified 
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prior to take subsequent steps; for instance, to distinguish an impurity which is 
simply derived from API alone or actually derived from interaction products of API-
excipient, excipient-excipient, or API-residual impurities existing in excipients [4–6].
Despite an increase in the research of impurities, a number of problems are still 
arisen in the development of identification technologies for degradation products 
and pathways. The first aim of this research is to address a brief review of the 
current major international regulatory requirements regarding the management of 
impurities in pharmaceutical products. Then secondly, a general scheme to establish 
an analytical method and acceptance criteria of degradation-related impurities 
(DRIs) and process-related impurities (PRIs) can be proposed, accordingly. Finally, 
our research will focus on developing a practicable algorithm to perform the iden-
tification of DPIs by using high-performance liquid chromatography tandem mass 
spectrometry (LC-MS/MS). Meanwhile, verification method for the justification of 
reliabilities regarding identification results will be assessed.
1.1 Classification of impurities
According to the definitions of International Council for Harmonization (ICH), 
Food and Drug Administration (FDA), and USP, impurities are classified into DRIs, 
PRIs, residual solvents, and heavy metals as shown in Figure 1 [1, 2, 7].
Two types of impurities might be API-related. The first type of API-related 
impurities is generated by degradation of API itself under specific storage condi-
tions, e.g., oxidation, dehydration, carbon dioxide removal, etc. The other type is 
occurred due to the interaction between API and excipients, container, or residual 
impurities in excipients, reagents, or solvents [8, 9]. API-related impurities are 
potentially genotoxic, mutagenic, and carcinogenic risk due to their structure-
activity relationship (SRA) [10, 11].
Figure 1. 
Classification of impurities [1, 2, 7].
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It is well known that excipients or the residual impurities in excipients can be 
very likely to cause instability of the API and drug product. A lot of impurities 
in excipients, such as presence of reactive peroxides or high water content in 
povidone or polyethylene glycols (PEGs), antioxidants in magnesium stearate, 
aldehydes in lactose, benzaldehyde in benzyl alcohol, formaldehyde in starch, 
lignin and hemicelluloses in microcrystalline cellulose were illustrated to 
demonstrate how reactive chemical entities are commonplace in excipients and 
incompatible to API. Some specific functional groups in API may be susceptible 
to degradation mechanisms, i.e., hydrolysis, oxidation, polymerization, etc. 
[4–6, 12–14].
Additionally, extractables and leachables such as initiators/catalysts, storage sta-
bilizers, antioxidants, processing aids, light stabilizers, antistatic agents, colorants, 
lubricants associated with pharmaceutically relevant materials may also produce 
uncertain risks to the stability or quality of products [15].
Regardless of the classes of impurities, presence of impurities may have the 
potential to affect the quality, safety, and efficacy of drug products. Therefore, 
studies of impurities are one of the most important works in the development of 
APIs and drug products [1, 16, 17].
1.2 Aims to conduct impurity study
Study of impurities in pharmaceuticals is one of the most highly regarded topics; 
it is essential, but time consuming and challenging. In terms of regulations and 
technology, we must keep pace with the times [18, 19]. Comprehensively speaking, 
aims to develop an impurity study have two major directions as follows: regulatory 
requirements and scientific/technical demands (Table 1).
From the perspective of regulatory requirements, impurities may affect the 
quality of APIs and DPs and ultimately affect the safety of the patient. Views 
for the dealing of impurities may differ between biologists, toxicologists, and 
analytical chemists, and therefore need to be integrated [20]. Potential genotoxic 
impurities can be determined according to the published literature, results of gene 
mutation in bacteria, in vitro and in vivo tests of chromosomal damage in mam-
malian cells or rodent hematopoietic cells, or/and comparative structural analysis 
to identify chemical functional moieties correlated with mutagenicity [16].  
Moreover, daily exposure, duration of exposure on the effects of degradation 
products and genotoxic impurities, and theoretical clinical dose, whereas potential 
Regulatory requirements Scientific and technical requirements
• Quality and safety of products
• Method validation, i.e., specificity
• Acceptance criteria determination
• Expiry date, retest date, and shelf-life evaluation
• Stability and storage conditions study
• Threshold limits evaluation, i.e., threshold of 
toxicological concern (TTC), permitted daily 
exposure (PDE), etc.
• Synthetic and production processes 
optimization
• Formulation development and optimization
• Efficacy improvement
• ADME and toxicology study
• Manufacturing of reference materials
• Stability improvement
• DPIs and pathways prediction
• Cost consideration
Table 1. 
Examples of the aims to conduct impurity studies [20, 23, 25–27].
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mutagenic impurities must be controlled to levels less than the threshold of toxi-
cological concern based on lifetime exposure shall be evaluated as a risk consider-
ation [16–18].
Adequate qualification must include genotoxicity and repeat-dose toxicology 
studies of appropriate duration to support the proposed indication. Moreover, 
other specific toxicity studies, e.g., embryofetal developmental toxicity study may 
be appropriate. Genotoxic impurities and degradation products pose an addi-
tional risk and should be controlled in accordance with the requirements of ICH 
M7(R1), unless they are qualified for safety [18, 21].
In addition to the regulatory requirements, internal and external scientific and 
technical needs are the second perspective to conduct an impurity study. Impurity 
determination and forced degradation studies are two of the basic requirements as a tool 
to predict potential DPIs, to develop analytical method, synthetic processes, and formu-
lation, to receive a better understanding of storage conditions, stability of drug product, 
and to obtain information of degradation products/pathways, as well as to evaluate the 
specificity (selectivity) of assay method [22–25].
2. Regulatory requirements for the management of impurity
A number of international/local guidelines and guidances for the evaluation and 
control of impurities in drug substances and drug products have been published 
[1–3, 7–9, 21, 28–38]. Comparison of the application scopes in line with the impurity 
categories was drawn as indicated in Figure 2.
As said by the requirements of ICH Q3A(R2), all types of impurities present in 
API at a level greater than (>) the identification threshold must conduct studies to 
characterize their structures, no matter they are shown in any batch manufactured 
by the proposed commercial process or any degradation product observed in sta-
bility studies under recommended storage conditions. Specified identified impuri-
ties shall be included in the list of impurities along with specified unidentified 
impurities that are estimated to be present at a level greater than the identification 
threshold [2, 7, 33].
Briefly, five major steps for the management of degradation products, no matter 
they are degradation products of API or reaction products of API with excipient(s) 
or container closure system, have been requested by the ICH Q3B (R2) and sum-
marized as follows [3]:
Figure 2. 
Comparison of the application scopes of regulatory guidelines/guidance for the management of impurities in 
pharmaceutical products [7, 28–34]. *Not clearly stated in the regulation.
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1. Confirm which impurities are degradation products?
2. Monitor and/or specify the amount of all degradation products.
3. Summarize all degradation products during manufacture and stability studies.
4. Elucidate and justify a rational evaluation of possible degradation pathway in 
the drug product or interaction with excipients or container closure system.
5. Establish specifications of all degradation products, including specified identi-
fied, specified unidentified, unspecified degradation product with an accept-
ance criterion of not more than (≤) identification threshold described in Q3B 
(R2), and their total amount.
Specificity (selectivity) of the method applied to determine specified and unspeci-
fied degradation product shall be validated. This includes subjecting of API or drug 
products to stress studies of light, heat, humidity, acid and base hydrolysis, and oxida-
tion to evaluate the HPLC separation resolution, mass balance, etc. [3, 22, 24, 25].
Although Q3B (R2) was developed by ICH to provide guidance on impurities in 
drug products for new drug applications (NDAs), it is also considered to be appli-
cable to the drug products of abbreviated new drug application (ANDAs) [33].
Regulation requirements regarding genotoxic, mutagenic, and carcinogenic impu-
rities have been published and revised by European Medicine Agency (EMA), FDA, 
and ICH in 2006, 2008, and 2017, respectively, to describe how to perform assess-
ments and controls, including prevention and reduction of impurities [21, 28, 32].
Concept of threshold of toxicological concern (TTC) has been developed to 
define an acceptable intake for any unstudied chemical that poses a negligible risk 
of carcinogenicity or other toxic effects [21]. In general, exposure level of 1.5 μg per 
person per day (i.e., TTC) for each impurity can be considered as a common accept-
able qualification threshold for supporting marketing application. Any impurity 
found at a level below this threshold generally does not need further safety qualifi-
cation for genotoxicity and carcinogenicity concerns. The threshold is an estimate 
of daily exposure expected to result in an upper-bound lifetime risk of cancer of 
less than 10−6 (one in a million), a risk level that is thought to pose negligible safety 
concerns [21, 32].
Currently, ICH Q3C is the major guideline related to the management of residual 
solvents in API, excipients, and drug products (Figure 2). In general, solvents that 
are used in the manufacturing procedures are the required parts to determine [8]. 
Types of solvents are sorted according to their carcinogenic and genotoxic risks as 
follows [8, 37]:
1. Class 1: solvents obviously confirmed or strongly suspected to cause cancer in 
humans.
2. Class 2: nongenotoxic and possible carcinogenic risks in animals.
3. Class 3: low-toxic solvents.
Elemental impurities may arise from residual catalysts that were added inten-
tionally in synthesis, or may be present as impurities, e.g., through interactions with 
processing equipment or container/closure systems or by being present in compo-
nents of the drug product. Because elemental impurities pose toxicological concerns 
and do not provide any therapeutic benefit to the patient, their levels in drug 
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products should be controlled within acceptable limits. Appropriate documentation 
demonstrating compliance for detailed risk assessment, screenings, and validation 
data for release methods must be conducted [9, 30, 34].
Recommended maximum acceptable concentration limits for the residues of 
metal catalysts or metal reagents that may be present in pharmaceutical products 
were issued earlier by EMA [29, 30]. Another classification of impurities, i.e., 
elemental impurities that the pharmaceutical industry needs to comply with is 
defined recently in ICH Q3D [9]. Comparison for these classifications of residues 
of metal or elemental impurities in pharmaceutical products defined by EMA and 
ICH was indicated as shown in Figure 3. Several significant difference of elemental 
safety concerns between EMA and ICH, such as Cr, As, Cd, Hg, Pb, etc., can be 
found.
3.  Strategies to establish analytical methods and acceptance criteria of 
PRIs and DRIs
This chapter will be followed by a discussion of procedure to establish an 
analytical method and acceptance criteria of DRIs and PRIs.
Steps for the determination of potential degradation products, including a 
science-based risk assessment, can been addressed as below [11, 25]:
1. Stress studies of API.
2. Accelerated stability studies or kinetically equivalent shorter term stability 
studies.
3. Validation/verification by long-term stability studies of both the drug substance 
and formulated drug product.
An integrated scheme in accordance with the requirements of ICH for the 
establishment of analytical methods and acceptance criteria of PRIs and DRIs is 
proposed as demonstrated in Figure 4 [2, 3, 17, 22, 39, 40].
In general, when an unknown peak was found, no matter it was found in a stress 
or stability studies of API or drug product, the first step is to distinguish the classifi-
cation of unknown impurity belongs to. Different regulatory requirements of the 
Figure 3. 
Comparison for the classification of residues of metal and elemental impurities in pharmaceutical products by 
requirements of EMA and ICH Q3D [9, 29, 30].
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management for different kinds of impurities, i.e., PRIs and DRIs are required to 
apply. For instance, requirements of ICH Q3B(R2) and Q1A(R2) request that impu-
rities present in API need not be monitored or specified in the drug product unless 
they are also degradation products. Due to the probability of degradation during 
storage period and are likely to influence quality, safety, and/or efficacy, degrada-
tion impurities must be included into the plan of stability studies [39]. Meanwhile, 
degradation impurities can ultimately determine the expiration, retest, or shelf-life 
periods of API and drug products, by evaluating the intersection of extrapolation-
upper confidence limit and upper acceptance criterion of degradation product(s) 
[40]. Reporting threshold, identification threshold, and qualification threshold in 
the case of maximum daily dose ≤2 g/day of APIs administrated are illustrated in 
Figure 4 [17].
Structure of impurities present in API at a level greater than (>) the identifica-
tion threshold needs to be elucidated. An identified impurity content can be either 
Figure 4. 
Scheme to establish analytical methods and acceptance criteria of process-related impurities (PRIs) and 
degradation-related impurities (DRIs) according to the requirements of ICH guidelines [2, 3, 17, 22, 39, 40].
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determined by interpolation with calibration curve of reference material or calculated 
using the peak area of the main component, i.e., API. In contrast, unidentified impu-
rity content can only be determined using the peak area of API, no matter they are 
specified or unspecified impurities. Impurities with specific acceptance criteria are 
referred to as specific impurities, including identified and unidentified impurities [2].
Before conducting method validation, all of the impurities shall be verified by 
spiked or known addition to demonstrate they do exist under the “real” storage 
conditions such as accelerated or long-term storage conditions. Otherwise, it may 
not be necessary to examine specifically for certain degradation products if they are 
not formed under the “real” storage conditions [11, 25, 39].
The method for technology transfer to QC laboratory, i.e., receiving unit (RU) 
must be a well-validated and stability-indicating method. A method fails to pass 
the criteria of validation or technology transfer, investigation to clarify the root 
cause(s) and revalidation shall be initiated and conducted by the originating unit 
(OU) and approved by quality unit (QU).
4. Identification and validation of DRIs
4.1 Practice of kinetic study to distinguish PRIs and DRIs
Algorithms for the identification and verification of DRIs are proposed as 
indicated in Figure 5. Degradation reaction kinetics can be represented by a linear 
regression curve on an arithmetic or logarithmic scale [39]. Meanwhile, nature of 
degradation relationship is determined by the reaction kinetic constants and can 
be accordingly used to distinguish whether an impurity is DRI or PRI compound 
(Figure 5).
One example regarding how to distinguish PRIs and DRIs by kinetic study was 
illustrated as demonstrated in Figure 6. Analysis by HPLC revealed that some 
impurities were existed in one of our products. Kinetic study helps us to distinguish 
the type of impurities.
Plots of the impurity formation concentration ([A] or Ln[A]) versus time can 
obtain rate constant, i.e., the slope of a reaction in straight line as arithmetic (i.e., k0)  
or logarithmic (i.e., k1) scale. Furthermore, correlation coefficient (r) of linear 
regression analysis indicates a perfect positive correlation (r = 1) or conversely, 
there is no relationship between the two variables (r = 0).
The slopes and correlation coefficients of Pk#5, Pk#6, and Pk#7 indicated that 
they were not degradation-related products of API. But conversely, kinetic curves 
showed that Pk#1–4 and Pk#8 were degradation products. These results were also 
consistent with the findings of molecular weight results shown in LC-MS/MS (data 
not shown).
4.2 Unknown impurity structure elucidation using LC-MS/MS
As shown in Figure 5, the first step for structure elucidation is running full Q1 
scans in both positive ion mode and negative ion mode to locate the m/z of parent 
peak. In this step, sample solution is typically introduced directly into mass spec-
trometer (MS) at a flow rate of 10 μL/min using a syringe pump. However, since 
dimer or oligomer may also be one of the potential impurities, range of Q1 scan 
shall be as wide as possible, e.g., to mass number of 1000–1200 at least.
Carefully compare the difference of mass-to-charge (∆m/z) numbers between 
experimental and nominal values of parent (molecular) peak as well as their stable 
isotope distribution patterns and natural abundances. Previous study for the 
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elucidation of degradation pathways of ethyl cysteinate dimer (ECD), a significant 
∆m/z value of −2 in Q1 scan between experimental result (m/z = 323.60) and 
nominal result (m/z = 325.46) of parent peak was found and indicating that an 
intramolecular disulfide (S-S) product, i.e., [ECDS-S+H]
+, was the prominent form 
of ECD (not [ECD+H]+) in aqueous solution before labeling of radioisotope, i.e., 
technetium-99m for i.v. injection (Figure 7) [25].
Repeat the product ion scans, precursor ion scans, and neutral loss scans of 
API to establish its collision-activated dissociation (CID) fragmentation data-
base, including the optimal CID energies of each fragment and multiple reaction 
monitoring (MRM) pairs. Propose the promising structures of CID fragments 
and fragmentation pathways of API, accordingly. Provide the comparison of ∆m/z 
results between experimental and nominal values for each peak, which is related to 
the fragmentation to verify the reliability of proposed fragments and fragmentation 
pathways [24, 25].
Figure 5. 
Algorithms for the identification and verification of API-related degradation impurities (DRIs).
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Linear relationship within dynamic ranges for the quantitation of MRM pairs, 
i.e., correlation coefficients (r = 1) between precursor ions and product ions is 
another indication to verify high stability and reproducibility of fragmentation in 
CID conditions of tandem MS [24, 25].
Before using the MRM pairs for impurity scanning, interference of fragments 
generated from background, matrix, or contaminants such as plasticizers present in 
the solvents and mobile phase must be verified. Plasticizers, e.g., di(2-ethylhexyl) 
phthalate (DEHP) are one of the most common contaminants in organic solvents, 
including acetonitrile and alcohol [41].
Repeat the same procedures mentioned above in Figure 5 to obtain a compre-
hensive information of fragments for any available intermediates and degradation 
products which are received from synthetic division, from contract manufacturing 
organization (CMO), from a stress study, or stability study sample conducted by the 
R&D team.
Steps for the determination of impurities related to degradation of API are 
illustrated as follows:
Figure 6. 
Kinetic study of impurities formation by conducting stress studies to distinguish DRIs and PRIs.
Figure 7. 
Structures of (a) ethyl cysteinate dimer (ECD), (b) intramolecular disulfide (S-S) product of ECD, i.e., 
ECDS-S, and (c) intermolecular dimer of ECD and reducing agent (SnCl2), i.e., Sn(ECD)2 (DP#4) [25].
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1. Step 1: According to the CID fragments of API, intermediates, or/and degrada-
tion products, a list of potential core fragments, which may be related to the 
unknown component(s) is proposed.
2. Step 2: Predict a set of potential/extending MRM pairs in line with the list 
obtained in step 1 and then coupled it with the relevant (bio-) transformations 
under the storage conditions of APIs/drug products for conducting MS/MS 
scans.
3. Step 3: Conduct the precursor ion scans together with function of information-
dependent acquisition (IDA), where CID is automatically performed on the 
two highest intensity MS peaks to find the possible precursor ions containing 
core fragments established in step 2.
4. Step 4: Perform the reliability assessment by analysis commercial batches or 
long-term/accelerated stability samples to verify the identification results of 
step 3.
One preliminary study was illustrated as shown in Figure 8 can be used to detail 
the algorithms of Figure 5. Core fragment of m/z 243 was found in the MS/MS 
study of API. In the meantime, four potential extending core fragments, i.e., m/z 
183, m/z 185, m/z 197, and m/z 199 were obtained by the MS/MS studies of interme-
diate and degradation product (Step 1).
A total of five potential core fragments, coupled with the experience accumu-
lated by degradation products that may be produced by similar chemical struc-
tures and prediction of relevant (bio-) transformations reactions under storage 
conditions, such as oxidation (+O, +2O), dehydration (−H2O, −2(H2O)), remove 
of carbon dioxide, and remove of acetic acid, a set of MRM pairs for scanning is 
established (Step 2).
Conduct the precursor ion scans by coupled with the IDA function for automatic 
performing collision on the two highest intensity MS peaks in the targeting regions 
of HPLC (Step 3). (Note: IDA is a build-in function of API 4000 QTrap (AB Sciex) 
for conducting an automatic collision on the highest intensity peak(s) scan.)
4.3 Verification of degradation products (step 4)
In addition to the methods mentioned above, i.e., kinetic study and difference 
of mass-to-charge (∆m/z) between experimental and nominal results, three other 
evaluation methods to verify the reliability of the identification results are available: 
including verification by real samples, by stable isotope distribution patterns, and 
by mass balance.
1. Verification by real samples
Investigation results of unknown degradation product(s) must be verified 
by the “real samples”, i.e., commercial batches or long-term/accelerated stabil-
ity studies samples. Verification of reliability is achieved by comparison the 
difference of retention time (tR), MRM pairs, and stable isotope distribution 
patterns between real samples and stress study samples. If it is available, purified 
or enrichment sample of impurity can be spiked into a real sample for further 
verification.
2. Verification by stable isotope distribution patterns or natural abundances
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Each element, like a fingerprint, has its own unique stable isotope distribution 
patterns and natural abundances. Occasionally, stable isotope distribution patterns 
or natural abundances are available as a unique tool for structure characterization.
Ten, two, and two of uncommon patterns in the MS spectra as shown in 
Figure 9(a)–(c) were clearly indicated in our structure identification of ethyl 
cysteinate dimer (ECD) cold kit, (R)-N-methyl-3-(2-bromophenoxy)-3-
phenylpropanamine (MBPP), and methoxyisobutylisonitrile (sestamibi, or 
Cu(MIBI)4), respectively. These uncommon patterns were attributed to the 
contribution of stable isotope distributions of tin (Sn), bromine (Br), and cop-
per (Cu), respectively.
When 7 major (or actually total 10) peaks are shown in the MS spectra, it may 
strongly mislead the works of structure elucidation as shown in Figure 9(a). 
However, if it is available to know the presence of some special elements may pres-
ent in impurity.
If it is able to presuppose that some special elements may contain in the struc-
ture, then it will be easier to elucidate the MS spectra. In other words, when pattern 
of MS spectra is significantly different from the normal CHO distribution, it may 
also indicate that a special element exists on the structure.
By comparing the natural abundance of 10 stable isotopes of tin and simulation 
MS spectra of a promising molecular formula, a series of metal complexes of tin 
can be verified. In the case for study of impurities in ECD kit, it was an ultimate and 
effective way to identify all of impurities containing Sn, i.e., DP#4, DP#5, DP#6, 
DP#6′, DP#6″, DP#7, DP#7′, DP#7″, and DP#8 [25]. Similar case was found in 
Figure 8. 
Step for the establishment of potential extending core fragments, conduct of product ions screening with 
transformation/IDA function, and validation/verification.
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the structure determination of sestamibi as shown in Figure 9(c). Coordination 
number (CN = 4) and core metal (Cu) in sestamibi can be clearly verified.
3. Verification by mass balance
When performing a stress study of API, one should determine content of API 
on each day by using a daily and freshly prepared calibration curve of API reference 
material, and interpolated within the validated dynamic range. The mass balance is 
Figure 9. 
Stable isotope distribution patterns and simulation of mass spectra of (a) Sn(ECD)2 (DP#4), (b) (R)-N-
methyl-3-(2-bromophenoxy)-3-phenylpropanamine (MBPP), and (c) methoxyisobutylisonitrile (sestamibi).
Quality Management and Quality Control - New Trends and Developments
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calculated by summation of the API and total impurity content. It is a tool to justify 
whether there are impurities unseparated (i.e., same retention time) or undetect-
able (e.g., without UV-visible chromophores). This topic and several major prob-
lems to cause poor mass balance have been detailed by Nussbaum et al. [42]
5. Conclusions
Management of impurities related to APIs in pharmaceutical products must be 
implemented in strict compliance with the regulatory requirements of pharma-
ceutical industry due to their quality and safety concerns. An integrated scheme in 
accordance with the regulatory requirements to establish analytical methods and 
acceptance criteria of process-related impurities (PRIs) and degradation-related 
impurities (DRIs) was presented, accordingly. Meanwhile, procedures for the iden-
tification and validation/verification of API-related DRIs were proposed. Validation 
or verification methods to evaluate the reliability of structure identification such as 
kinetic reactions, stress and stability studies, comparison of retention time(s) and 
∆m/z between experimental and nominal values of targeting peaks, compatibility 
of MRM pairs with “real samples,” stable isotope distribution patterns, and mass 
balance were demonstrated. Applying of the processes proposed in this article will 
help to ensure the reliability and quality of the impurity analytical results.
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